Non-obstructive Hypertrophic Cardiomyopathy clinical trials at UCSF
1 in progress, 1 open to new patients
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
open to eligible people ages 18 years and up
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.
San Francisco, California and other locations